1 2	Exploring plasma cell motility and extracellular matrix protein biomarkers for primary progressive multiple sclerosis: A pilot study
3	
4	Exploring extracellular matrix proteins as MS progression biomarkers
5	
6	
7	Elijah Lackey ^{1*}
8	Stephanie Reinke ¹
9	Sheng Luo ²
10	Daniel Laskowitz ³
11	Christopher Eckstein ¹
12	Simon G Gregory ^{1, 4}
13	
14 15	¹ Division of MS & Neuroimmunology, Department of Neurology, Duke University, Durham, NC, United States of America
16 17	² Division of Biostatistics, Department of Biostatistics & Bioinformatics, Duke University, Durham, NC, United States of America
18 19	³ Division of Neurocritical Care, Department of Neurology, Duke University, Durham, NC, United States of America
20	⁴ Department of Neurosurgery, Duke University, Durham, NC, United States of America
21	
22	
23	* Corresponding author: Elijah Lackey, MD Elijah.lackey@duke.edu (EL)
24	
25	
26	
27	
28	Abstract
29	Primary progressive multiple sclerosis is associated with neurodegeneration and chronic inflammation,
30	and results in the accumulation of gradual disability. This pilot study investigated 92 plasma proteins

Introduction

Multiple sclerosis (MS) is the most common autoimmune disease affecting the central nervous system.

(1) MS causes both inflammatory relapses and a more insidious neurodegeneration referred to as progression. Recently, a paradigm shift has occurred in our understanding of disability accumulation in MS with the knowledge that progression contributes to disability accrual more than relapses.(2, 3) Multiple high-efficacy MS disease modifying therapies are available that effectively prevent relapses, but their effect on progression remains poorly understood. Because of this new focus on progression as a clinical target, there is greater need for disease-specific biomarkers that can monitor its development and track its severity.

Current blood biomarkers, such as neurofilament light chain and glial fibrillary acidic protein, can be increased by a wide variety of neurologic diseases.(4, 5) This lack of specificity has prevented their widespread clinical use for managing MS. Similarly, although some cerebrospinal fluid biomarkers such as SERPINA3 have shown promise, they are not practical for tracking disease activity longitudinally.(6)

New disease and progression specific blood biomarkers will need to be discovered to translate effectively to the clinic.

In this pilot study, we targeted plasma proteins previously implicated in MS pathophysiology to

In this pilot study, we targeted plasma proteins previously implicated in MS pathophysiology to identify specific markers of progression (Table 1). The panel we selected includes many proteins previously hypothesized to play a role in MS pathophysiology, neurodegeneration, or remyelination. We explored whether individual proteins or a group of proteins from this panel could distinguish between MS phenotypes and used selected proteins in a predictive model for primary progressive MS. Primary progressive MS was chosen as the phenotype of interest because these patients experience the greatest degree of progression.(3) A commercially available panel of proteins (Olink Development Target 96, Olink Waltham, MA) was selected that focuses on cell migration and extracellular matrix organization.

Materials and methods

such as Laminin A4, Aggrecan, and PARK7 (S1 Table).(7, 8, 9)

Duke University IRB exemption was obtained (Pro00112531). Samples were obtained from adult patients (age >18) who participated in the MURDOCK (Measurement to Understand Reclassification of Disease Of Cabarrus and Kannapolis) study diagnosed with secondary progressive (SP), primary progressive (PP) or relapsing remitting (RR) MS. The MS cohort includes 25 PP patients, 88 SP patients, and 966 RR patients. Controls were derived from the greater MURDOCK study, which includes 12,526 patients. Samples were collected and stored (-80C) in a standardized process for the MURDOCK repository from 3/2009 to 8/2016. Clinical data was accessed August 4th, 2023. The authors did not have access to identifiable data for participants either before or after data collection. EDTA plasma samples were matched by age, sex, disease modifying therapy, and race (1:1:1:1). We excluded patients with recent radiographic relapse or treatment with steroids (within 30 days). MS diagnosis and relapses were self-reported by patients. Sample analysis was performed using Olink proximal extension assay,

Results

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Samples were matched for age, sex, disease-modifying therapy (for MS patients), and race (Table 1).

	Primary Progressive	Secondary Progressive	Relapsing Remitting	Controls
Age, mean (SD)	57.4 (8.8)	53.8 (9.9)	49.9 (9.4)	49.6 (9.7)

Female Sex, n (%)	12 (54.5)	17 (77.3)	18 (81.8)	15 (68.1)	
Most Common DMT	Interferon Beta-1a	Interferon Beta-1a	Glatiramer acetate	none	
Race, n (%)					
White/Caucasian	18 (81.8)	20 (90.9)	18 (81.8)	19 (86.4)	
Black/African American	4 (18.2)	2 (9.1)	4 (18.1)	3 (13.6)	

Table 1. Summary statistics after matching on age, sex, MS disease-modifying therapy, and race. After randomization across the plate, samples were analyzed per the Olink platform protocol. All samples and assays met the platform's quality control measures. ANOVA resulted in five proteins; aggrecan (ACAN), thymosin beta-10 (TMSB10), ADP-ribosyl cyclase (BST1), C-type lectin domain family 11 member A (CLEC11A), and myocilin (MYOC) with p-values less than 0.05. Although none of the proteins remaining statistically significant after Bonferroni correction (adjusted p value 0.0005), five proteins of interest were incorporated into logistic regression and support vector machine models comparing on an all-vs-one basis (PP vs all other groups including control). Logistic regression yielded an accuracy of 0.69 and the support vector machine an accuracy of 0.68 (Fig 1).

Fig 1. Receiver operating characteristic curves and accuracies for the support vector and logistic regression models

Discussion

As clinical priorities for the care of patients with MS shift toward a focus on progression, we need better biomarkers to quantify disease activity. We now know that progression plays a pivotal role in MS-related disability accrual.(3) This new perspective has sparked a need for more specific and readily accessible biomarkers to monitor and differentiate the extent of progression among MS patients. The choice of blood biomarkers in our study was deliberate, as they offer practicality and clinical utility. We refrained from revisiting well-established markers of neuronal injury and instead focused on a

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

6

encephalomyelitis (EAE) pathogenesis.(14) Myocilin (MYOC), to our knowledge, has not been previously

Our study has several limitations. Its reliance on self-reported MS diagnoses, based on outdated diagnostic criteria, is certainly a limitation. The relatively small sample size is also a constraint to be considered. Future studies with larger cohorts and samples from patients with more recent diagnoses, using the latest diagnostic criteria, are needed to advance our understanding of MS progression and to discover disease-specific biomarkers.

Conclusions

This pilot study provides a preliminary exploration into plasma biomarkers for MS progression, with a specific focus on biomarkers predictive of primary progressive MS. Five proteins were identified; ACAN, BST1, TMSB10, CLEC11A, and MYOC that differentiate subtypes of MS with p <0.05. While none of the individual proteins achieved statistical significance after correction for multiple comparisons, these proteins show potential for further investigation. Importantly, myocilin (MYOC) is a secreted glycoprotein that has not previously been implicated in MS pathophysiology or investigated as a biomarker. The need for further research to validate and expand upon these findings remains pressing, particularly in the context of emerging treatments targeting MS progression.

Acknowlegments

This work was made possible through the use of the MURDOCK Study and Duke University's CTSA grant (UL1TR002553) from the National Institutes of Health (NIH)'s National Center for Advancing Translational Sciences (NCATS).

S1 Table. Proteins from the Olink Target 96 Development Panel Implicated in MS or EAE Pathophysiology

Biologic Function	Protein and references
Extracellular Matrix Proteins	Laminin A4 (7)
	Aggrecan (8, 10)
	Matrilin-2 (16)
cell Differentiation and Regulation	Fc receptor-like protein 5 (17, 18, 19)
	Macrophage migration inhibitory factor (20)
	HLA class II histocompatibility antigen gamma chain (CD74) (20)
	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 (BST1) (12)
	Lymphocyte function-associated antigen 3 (CD58) (21)
Leukocyte adhesion and migration	CD99 antigen-like protein 2 (CD99L2) (22)
	C-C motif chemokine 21 (CCL21) (23, 24)
	CD177 antigen (CD177) (25)
Mitochondrial homeostasis and antioxidant defenses	CD97 (26) PARK7 (9) HTRA2 (27)
Angiogenesis	PDGRFB (28, 29)
Lysosomal degradation	LGMN (30)

Supplemental Table 1. Proteins in the Olink Target 96 Development Panel with prior evidence for involvement in experimental autoimmune encephalomyelitis (EAE) or multiple sclerosis (MS).

^{1.} Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019;92(10):e1029-e40.


^{2.} Tur C, Carbonell-Mirabent P, Cobo-Calvo A, Otero-Romero S, Arrambide G, Midaglia L, et al. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis. JAMA Neurol. 2023;80(2):151-60.

- 178 3. Lublin FD, Haring DA, Ganjgahi H, Ocampo A, Hatami F, Cuklina J, et al. How patients with
- multiple sclerosis acquire disability. Brain. 2022;145(9):3147-61.
- 4. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, et al. Blood GFAP as an
- emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-72.
- 182 5. Shahim P, Politis A, van der Merwe A, Moore B, Ekanayake V, Lippa SM, et al. Time course and
- diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology.
- 184 2020;95(6):e623-e36.
- 185 6. Fissolo N, Matute-Blanch C, Osman M, Costa C, Pinteac R, Miro B, et al. CSF SERPINA3 Levels Are
- 186 Elevated in Patients With Progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2).
- 187 7. van Horssen J, Dijkstra CD, de Vries HE. The extracellular matrix in multiple sclerosis pathology. J
- 188 Neurochem. 2007;103(4):1293-301.
- 189 8. Keough MB, Rogers JA, Zhang P, Jensen SK, Stephenson EL, Chen T, et al. An inhibitor of
- 190 chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat
- 191 Commun. 2016;7:11312.
- 192 9. Vavougios GD, Zarogiannis SG, Krogfelt KA, Gourgoulianis K, Mitsikostas DD, Hadjigeorgiou G.
- 193 Novel candidate genes of the PARK7 interactome as mediators of apoptosis and acetylation in multiple
- sclerosis: An in silico analysis. Mult Scler Relat Disord. 2018;19:8-14.
- 195 10. Lin JZ, Duan MR, Lin N, Zhao WJ. The emerging role of the chondroitin sulfate proteoglycan
- family in neurodegenerative diseases. Rev Neurosci. 2021;32(7):737-50.
- 197 11. Pu A, Stephenson EL, Yong VW. The extracellular matrix: Focus on oligodendrocyte biology and
- targeting CSPGs for remyelination therapies. Glia. 2018;66(9):1809-25.
- 199 12. Liguori M, Nuzziello N, Simone M, Amoroso N, Viterbo RG, Tangaro S, et al. Association between
- 200 miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study.
- 201 Brain Behav. 2019;9(2):e01199.
- 202 13. Severa M, Zhang J, Giacomini E, Rizzo F, Etna MP, Cruciani M, et al. Thymosins in multiple
- sclerosis and its experimental models: moving from basic to clinical application. Mult Scler Relat Disord.
- 204 2019;27:52-60.
- 205 14. N'Diaye M, Brauner S, Flytzani S, Kular L, Warnecke A, Adzemovic MZ, et al. C-type lectin
- 206 receptors Mcl and Mincle control development of multiple sclerosis-like neuroinflammation. J Clin
- 207 Invest. 2020;130(2):838-52.
- 208 15. Aroca-Aguilar JD, Fernandez-Navarro A, Ontanon J, Coca-Prados M, Escribano J. Identification of
- 209 myocilin as a blood plasma protein and analysis of its role in leukocyte adhesion to endothelial cell
- 210 monolayers. PLoS One. 2018;13(12):e0209364.
- 211 16. Jonas A, Thiem S, Kuhlmann T, Wagener R, Aszodi A, Nowell C, et al. Axonally derived matrilin-2
- 212 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. J Clin Invest.
- 213 2014;124(11):5042-56.
- 214 17. Chorazy M, Wawrusiewicz-Kurylonek N, Adamska-Patruno E, Czarnowska A, Zajkowska O,
- 215 Kapica-Topczewska K, et al. Variants of Novel Immunomodulatory Fc Receptor Like 5 Gene Are
- 216 Associated With Multiple Sclerosis Susceptibility in the Polish Population. Front Neurol. 2021;12:631134.
- 217 18. Comabella M, Canto E, Nurtdinov R, Rio J, Villar LM, Picon C, et al. MRI phenotypes with high
- 218 neurodegeneration are associated with peripheral blood B-cell changes. Hum Mol Genet.
- 219 2016;25(2):308-16.
- 220 19. Yuan M, Wei L, Zhou R, Bai Q, Wei Y, Zhang W, et al. Four FCRL3 Gene Polymorphisms (FCRL3_3,
- 5, 6, 8) Confer Susceptibility to Multiple Sclerosis: Results from a Case-Control Study. Mol Neurobiol.
- 222 2016;53(3):2029-35.
- 223 20. Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, et al. HLA-DRalpha1
- 224 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. J
- 225 Immunol. 2014;192(9):4164-73.


- 227 CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A. 2009;106(13):5264-9.
- 228 22. Samus M, Seelige R, Schafer K, Sorokin L, Vestweber D. CD99L2 deficiency inhibits leukocyte
- 229 entry into the central nervous system and ameliorates neuroinflammation. J Leukoc Biol.
- 230 2018;104(4):787-97.
- 23. Dhaiban S, Al-Ani M, Elemam NM, Maghazachi AA. Targeting Chemokines and Chemokine
- 232 Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Inflamm Res.
- 233 2020;13:619-33.
- 234 24. Bielecki B, Jatczak-Pawlik I, Wolinski P, Bednarek A, Glabinski A. Central Nervous System and
- 235 Peripheral Expression of CCL19, CCL21 and Their Receptor CCR7 in Experimental Model of Multiple
- 236 Sclerosis. Arch Immunol Ther Exp (Warsz). 2015;63(5):367-76.
- 237 25. Cordiglieri C, Baggi F, Bernasconi P, Kapetis D, Faggiani E, Consonni A, et al. Identification of a
- 238 gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-
- 239 modifying therapies. Clin Immunol. 2016;173:133-46.
- 240 26. Visser L, de Vos AF, Hamann J, Melief MJ, van Meurs M, van Lier RA, et al. Expression of the EGF-
- TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol. 2002;132(1-2):156-
- 242 63.

254

- 243 27. Maus F, Sakry D, Biname F, Karram K, Rajalingam K, Watts C, et al. The NG2 Proteoglycan
- 244 Protects Oligodendrocyte Precursor Cells against Oxidative Stress via Interaction with OMI/HtrA2. PLoS
- 245 One. 2015;10(9):e0137311.
- 246 28. Iacobaeus E, Sugars RV, Tornqvist Andren A, Alm JJ, Qian H, Frantzen J, et al. Dynamic Changes in
- 247 Brain Mesenchymal Perivascular Cells Associate with Multiple Sclerosis Disease Duration, Active
- 248 Inflammation, and Demyelination. Stem Cells Transl Med. 2017;6(10):1840-51.
- 249 29. Sekerdag-Kilic E, Ulusoy C, Atak D, Ozkan E, Gokyuzu AB, Seyaj S, et al. Perivascular PDGFRB+
- 250 cells accompany lesion formation and clinical evolution differentially in two different EAE models. Mult
- 251 Scler Relat Disord. 2023;69:104428.
- 30. Huynh JL, Garg P, Thin TH, Yoo S, Dutta R, Trapp BD, et al. Epigenome-wide differences in
- pathology-free regions of multiple sclerosis-affected brains. Nat Neurosci. 2014;17(1):121-30.



Figure



MYOC

CLEC11A

BST1

Figure

TMSB10

ACAN